Biotricity BTCY

Biotricity Inc. is a medical technology company focused on biometric data monitoring solutions for diagnostic and post-diagnostic applications in the medical, healthcare, and consumer markets. The company specializes in remote cardiac monitoring technologies that integrate hardware devices with software platforms to provide continuous ECG monitoring and arrhythmia detection. Biotricity aims to deliver cost-effective solutions that support clinicians in diagnosing and managing chronic cardiac conditions while generating recurring technology fee revenue through its insourcing business model.

Biotricity generates revenue primarily through utilization-based recurring technology fees charged to healthcare providers for the use of its remote monitoring devices and associated software platforms. The company earns revenue by placing its diagnostic and chronic care management devices with physician offices, clinics, hospitals, and independent diagnostic testing facilities, which then bill payers for cardiac monitoring services. Biotricity's revenue model is structured as a technology-as-a-service approach where it retains ownership of the devices and charges service fees based on utilization, rather than selling equipment outright.

The company operates through the following segments: Cardiac Diagnostics, Holter/Extended Holter Monitoring, and Chronic Care Management and Remote Patient Monitoring.

• Cardiac Diagnostics: This segment focuses on ambulatory diagnostic cardiac outpatient monitoring (COM) solutions for physicians and medical facilities. Biotricity's Bioflux® and Biocore Pro devices are FDA-cleared three-lead ECG monitoring systems with built-in cellular connectivity that enable real-time data transmission and arrhythmia analysis. The Bioflux device received full market release in April 2019, while the Biocore Pro, launched in late 2024 as the cellular version of the Biocore device, is now the company's flagship technology for COM applications.
• Holter/Extended Holter Monitoring: This segment provides connected three-lead patch solutions for Holter and extended Holter monitoring applications, targeting lower-risk patients and broader market segments. The Biocore Cardiac Monitoring Device, previously branded as Biotres, received 510(k) FDA clearance in January 2022 and offers improved arrhythmia detection compared to traditional one-lead Holter monitors. The Biocore device reduces time to diagnosis from up to two weeks to three days or less through its connected three-lead ECG capability and rechargeable, reusable design.
• Chronic Care Management and Remote Patient Monitoring: This segment delivers consumer and clinical solutions for ongoing cardiac disease management and multi-condition remote monitoring. Biotricity's Bioheart direct-to-consumer heart monitor, launched in 2021, provides continuous heart rhythm monitoring using the same technology as its clinical devices and was recognized as one of TIME's Best Inventions of 2022. The Biocare platform integrates cardiac diagnostics with biometric reporting, patient dashboards, automated reminders, and virtual clinic capabilities to support chronic care management for patients with multiple conditions such as hypertension or COPD, while the Biokit combines blood pressure, oxygen saturation, and temperature monitoring with the Biocare platform.

Biotricity occupies a competitive position in the remote cardiac monitoring market by offering differentiated technology that combines three-lead ECG monitoring with built-in cellular connectivity in a single-piece solution, which contrasts with many competitors' two-piece, one- or two-lead systems requiring separate software acquisition. The company's insourcing business model enables physicians to bill for monitoring services directly, creating a disruptive alternative to the outsourced models employed by competitors such as Philips Biotel (BioTelemetry) and Boston Scientific–Preventice, which retain reimbursement and pay physicians only administrative stipends. Biotricity's technological advantages include superior data quality from three-channel ECG collection, improved patient compliance through wearable design, and operational efficiency from real-time data transmission and automated reporting, which together create barriers to entry for new and existing competitors seeking to replicate its integrated platform approach.

Biotricity serves physician offices, clinics, hospitals, and independent diagnostic testing facilities (IDTFs) across 35 states, with a strategic focus on cardiologist practices, cardiology-specialized hospitals, and cardiac monitoring IDTFs. The company targets approximately 34,000 cardiologist physician offices, 780 cardiology-specialized hospitals, and 300 cardiac-focused IDTFs in the United States as part of its addressable market for both diagnostic and chronic care management solutions. Biotricity's technology is deployed in clinical settings to support healthcare providers in delivering reimbursable cardiac monitoring services to patients undergoing ambulatory ECG studies or managing chronic cardiovascular conditions.